GMB To Give Evidence To BIS Parliamentary Committee On Tuesday 13th May On Pfizer Bid For Astra Zeneca
Unions will press the Committee that Pfizer is not to be trusted with this national asset either in terms of manufacturing or in terms of crucial research and development says GMB.
GMB, the union for workers at Astra Zeneca, will give evidence to the House of Commons Business, Innovation and Skills Committee on Pfizer's proposed takeover of AstraZeneca on Tuesday 13 May.
The Committee will be hearing from trade unions, together with the Chairman and Chief Executive of Pfizer Inc. and AstraZeneca plc.See notes to editors for copy of the BIS announcement.
Allan Black, GMB National Officer, said “I welcome the opportunity to explain to this important Parliamentary Committee the concerns we have should Pfizer make a bid, hostile or otherwise, which leads to them taking ownership of Astra Zeneca.
GMB believe that the record of Astra Zeneca in discovering and developing life-saving and life enhancing drugs is one to be proud of. It has been a key part of making the UK a world leader in the industry.
GMB will be trying to press the Committee to the view that based on their dubious track record Pfizer is not to be trusted with this national asset either in terms of manufacturing or in terms of crucial research and development."
Contact: Allan Black 07725 100316 or Eddie Parker 07740 804046 or GMB press office 07921 289880
Notes to editors
Business, Innovation and Skills Committee
Select Committee Announcement No.57- 7 May, 2014
EVIDENCE SESSION ON THE FUTURE OF ASTRAZENECA
The Business, Innovation and Skills Committee will be taking evidence on Pfizer's proposed takeover of AstraZeneca on Tuesday 13 May. The Committee will be hearing from trade unions, together with the Chairman and Chief Executive of Pfizer Inc. and AstraZeneca plc.
Tuesday 13 May 2014
Committee Room tbc
* Tony Burke, Assistant General Secretary, Unite
* Allan Black, National Officer, GMB
* Ian Read, Chairman and Chief Executive, Pfizer Inc. (lead witness)
* Pascal Soriot, Chief Executive Officer, AstraZeneca PLC (lead witness)
The session will be open to the public on a first come, first served basis. There is no system for the prior reservation of seats in Committee Rooms. It is advisable to allow about 20 minutes to pass through security checks. Committee Rooms and timings are subject to change.
Committee Membership is as follows:
Chair: Mr Adrian Bailey MP (Lab) (West Bromwich West)
Mr William Bain MP (Lab) (Glasgow North East) Mr Brian Binley MP (Con) (Northampton South)
Paul Blomfield MP (Lab) (Sheffield Central) Katy Clark MP (Lab) (North Ayrshire and Arran)
Mike Crockart MP (Lib Dem) (Edinburgh West) Caroline Dinenage MP (Con) (Gosport)
Rebecca Harris MP (Con) (Castle Point) Ann McKechin MP (Lab) (Glasgow North)
Mr Robin Walker MP (Con) (Worcester) Nadhim Zahawi MP (Con) (Stratford upon Avon)
Media Information: David Foster email@example.com<mailto:firstname.lastname@example.org> 020 7219 7556/07917 488729
Committee Website: www.parliament.uk/bis<;http://www.parliament.uk/bis>
Specific Committee Information: email@example.com/<mailto:firstname.lastname@example.org/> 020 7219 5777/5779
Watch committees and parliamentary debates online: www.parliamentlive.tv<;http://www.parliamentlive.tv/>